EPS for Agenus Inc. (AGEN) Expected At $-0.25

October 13, 2018 - By Dolores Ford

Agenus Inc. (NASDAQ:AGEN) LogoInvestors sentiment decreased to 1.02 in 2018 Q2. Its down 0.44, from 1.46 in 2018Q1. It dropped, as 22 investors sold Agenus Inc. shares while 21 reduced holdings. 17 funds opened positions while 27 raised stakes. 40.51 million shares or 12.82% less from 46.47 million shares in 2018Q1 were reported.
Fisher Asset Mngmt Lc stated it has 0% of its portfolio in Agenus Inc. (NASDAQ:AGEN). California State Teachers Retirement System holds 0% or 122,358 shares. New York-based Tiaa Cref Invest Limited Liability Company has invested 0% in Agenus Inc. (NASDAQ:AGEN). Bluecrest Mngmt holds 0% or 20,300 shares in its portfolio. Citadel Ltd reported 783,835 shares. Oracle Invest Mgmt invested in 1.50M shares. Bankshares Of America De owns 78,001 shares. Blackrock Inc accumulated 5.72 million shares. Hudson Bay Capital Limited Partnership stated it has 500,000 shares. Stifel Corporation holds 0% or 10,066 shares. Great West Life Assurance Can holds 0% or 8,800 shares in its portfolio. Citigroup holds 50,400 shares. Jpmorgan Chase owns 16,235 shares. Blair William And Co Il invested in 0% or 58,410 shares. Ubs Asset Mgmt Americas Incorporated holds 132,999 shares.

Analysts expect Agenus Inc. (NASDAQ:AGEN) to report $-0.25 EPS on November, 6.They anticipate $0.12 EPS change or 32.43 % from last quarter’s $-0.37 EPS. After having $-0.24 EPS previously, Agenus Inc.’s analysts see 4.17 % EPS growth. The stock decreased 2.50% or $0.05 during the last trading session, reaching $1.95. About 704,625 shares traded. Agenus Inc. (NASDAQ:AGEN) has declined 53.28% since October 13, 2017 and is downtrending. It has underperformed by 68.90% the S&P500.

Agenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system for patients suffering with cancer. The company has market cap of $220.90 million. The firm offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies. It currently has negative earnings. It is also developing checkpoint modulating antibody candidates targeting GITR, OX40, TIM-3, and LAG-3.

More important recent Agenus Inc. (NASDAQ:AGEN) news were published by: Benzinga.com which released: “26 Stocks Moving In Thursday’s Pre-Market Session” on October 11, 2018, also Nasdaq.com published article titled: “Recent Analysis Shows Ryman Hospitality Properties, PennantPark Investment, PS Business Parks, Agenus, Belden …”, Seekingalpha.com published: “Agenus secures $40M capital raise” on October 11, 2018. More interesting news about Agenus Inc. (NASDAQ:AGEN) was released by: Prnewswire.com and their article: “Agenus To Present Data on Proprietary CTLA-4 & PD-1 Antibodies at ESMO 2018” with publication date: October 09, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>